Clinical trial SKYGLO
A Phase III, multicenter, randomized, open label study comparing the efficacy and safety of Glofitamab (RO7082859) in combination with Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-Chp) versus Pola R Chp in previously untreated patients with large B-cell Lymphoma (SKYGLO - GO44145)
| Organ | Lymphoma |
|---|---|
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Roche |
| EudraCT Identifier | 2023-504028-24-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06047080 |
| Inclusion criteria | large B-cell Lymphoma |
| Last update |